Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

OncLive.com· @OncLive · X·2026-04-21 06:54· 2026-04-21Score60

Reading

Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T

CAR-PRISM’s universal MRD negativity happened in a window of healthier T cells and lower burden; solid tumors do not have that window yet.

Body

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.
@OmarNadeemMD

@DanaFarber

@AACR
#AACR26 #mmsm #hematology

Heat 4 · 4 likes · 0 replies · 0 reposts

Source: OncLive.com · x.com